OKYO
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited (OKYO) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | D- (0.9) | C (2.2) | C (2.5) | C+ (2.6) | C (2.2) |
| 2026-11-06 | C+ (2.5) | D- (0.9) | C (2.2) | C+ (2.5) | C+ (2.7) | C (2.2) |
| 2026-10-30 | C+ (2.5) | D- (1.0) | C (2.3) | C- (2.1) | C+ (2.7) | C- (2.1) |
| 2026-10-23 | C+ (2.5) | D- (1.0) | C (2.2) | C (2.2) | C+ (2.6) | C- (2.1) |
| 2026-10-16 | C+ (2.5) | D- (1.0) | C (2.2) | C (2.4) | C+ (2.6) | C- (2.1) |